CKD Bio Q3 Revenue Falls 14% Year on Year
Bitget2026/10/30 05:33- CKD Bio’s third-quarter 2026 operating loss widened 308.6% year over year to 5.99 billion won.
- Revenue fell 14% year over year to 29.33 billion won.
- Net loss widened 381% year over year to 10.48 billion won.
- First-nine-month operating results swung to a 12.7 billion won loss from a 3.5 billion won profit a year earlier.
- Revenue for that period declined 5.7% year over year to 111.11 billion won.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
